Curis (CRIS) Competitors $3.09 -0.01 (-0.29%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$3.10 +0.01 (+0.45%) As of 02/21/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CRIS vs. AGEN, RGLS, DOMH, FBIO, BOLT, SABS, MTEM, AMGN, GILD, and VRTXShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Agenus (AGEN), Regulus Therapeutics (RGLS), Dominari (DOMH), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "biotechnology" industry. Curis vs. Agenus Regulus Therapeutics Dominari Fortress Biotech Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Agenus (NASDAQ:AGEN) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Which has preferable valuation and earnings, AGEN or CRIS? Curis has lower revenue, but higher earnings than Agenus. Curis is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.50-$245.76M-$11.24-0.30Curis$10.02M2.61-$47.41M-$7.81-0.40 Do analysts rate AGEN or CRIS? Agenus presently has a consensus target price of $10.00, suggesting a potential upside of 201.20%. Curis has a consensus target price of $23.00, suggesting a potential upside of 644.10%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of AGEN or CRIS? 61.5% of Agenus shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 4.6% of Agenus shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, AGEN or CRIS? Agenus has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.41, indicating that its stock price is 241% more volatile than the S&P 500. Does the media refer more to AGEN or CRIS? In the previous week, Agenus' average media sentiment score of 0.00 equaled Curis'average media sentiment score. Company Overall Sentiment Agenus Neutral Curis Neutral Does the MarketBeat Community favor AGEN or CRIS? Curis received 226 more outperform votes than Agenus when rated by MarketBeat users. However, 69.19% of users gave Agenus an outperform vote while only 67.81% of users gave Curis an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.19% Underperform Votes20830.81% CurisOutperform Votes69367.81% Underperform Votes32932.19% Is AGEN or CRIS more profitable? Agenus has a net margin of -145.89% compared to Curis' net margin of -443.35%. Agenus' return on equity of 0.00% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Curis -443.35%-923.37%-78.35% SummaryCuris beats Agenus on 10 of the 16 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.18M$3.13B$5.77B$8.99BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.4030.1126.4618.82Price / Sales2.61386.80453.6978.73Price / CashN/A183.5344.0437.47Price / Book0.933.567.634.64Net Income-$47.41M-$71.72M$3.18B$245.69M7 Day Performance-4.01%-2.46%-1.91%-2.66%1 Month Performance-5.47%-0.25%-0.19%-2.15%1 Year Performance-68.56%-12.31%16.70%12.90% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.7996 of 5 stars$3.09-0.3%$23.00+644.1%-69.9%$26.25M$10.02M0.0060Gap UpAGENAgenus4.0871 of 5 stars$3.51+0.3%$10.00+184.9%-74.8%$82.35M$156.31M-0.31440Positive NewsRGLSRegulus Therapeutics2.5279 of 5 stars$1.21flat$10.80+792.6%-13.2%$79.26MN/A-1.1330DOMHDominari0.6039 of 5 stars$11.94-8.2%N/A+305.9%$75.70M$2.04M-3.094Gap UpHigh Trading VolumeFBIOFortress Biotech1.9017 of 5 stars$1.71-2.8%$13.67+699.2%-6.4%$47.20M$84.51M-0.56170BOLTBolt Biotherapeutics3.1554 of 5 stars$0.50+2.8%$3.50+597.5%-56.8%$19.20M$7.88M-0.2990SABSSAB Biotherapeutics2.3679 of 5 stars$1.98+13.1%$12.40+526.3%-64.8%$18.27M$2.24M0.00140MTEMMolecular TemplatesN/A$0.00+66.7%N/A-100.0%$3,000.00$57.31M0.00260Gap UpAMGNAmgen4.4673 of 5 stars$291.16-2.0%$314.09+7.9%+6.9%$156.51B$33.42B38.5626,700Insider TradePositive NewsGILDGilead Sciences4.7824 of 5 stars$104.08-1.8%$101.33-2.6%+50.2%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive NewsVRTXVertex Pharmaceuticals4.1169 of 5 stars$459.00-0.8%$505.57+10.1%+15.4%$118.21B$9.87B-230.655,400Analyst DowngradeInsider TradeAnalyst RevisionPositive News Related Companies and Tools Related Companies Agenus Competitors Regulus Therapeutics Competitors Dominari Competitors Fortress Biotech Competitors Bolt Biotherapeutics Competitors SAB Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRIS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRIS Stock Alerts